C-AQQMSenisca
RNA splicing, senotherapeutics, oligonucleotides
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AQQM
C-AQQMC-AQQMRNA splicing, senotherapeutics, oligonucleotides
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Presenting Companies ⇽ BioTrinity 2022 | BioUK on Glue Up This is a past event. Registration is closed. View other BioUK events. Log In Close Please enter a valid email address e.g. [email protected] Email Address * If you input more than 0 characters your Email Address may not display properly Afghanistan | 🇦🇫 + 93 Aland Islands | 🇦🇽 + 358 Albania | 🇦🇱 + 355 Algeria | 🇩🇿 + 213 American Samoa | 🇦🇸 + 1684 Andorra | 🇦🇩 + 376 Angola | 🇦🇴 + 244 Anguilla | 🇦🇮 + 1264 Antarctica | 🇦🇶 + 672 Antigua and Barbuda | 🇦🇬 + 1268 Argentina | 🇦🇷 + 54 Armenia | 🇦🇲 + 374 Aruba | 🇦🇼 + … input more than 0 characters your New Password may not display properly Cancel Submit Your password has expired. Change your password to continue. Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number , and one special character(!"#$%&'()*+,-./\:;?@[]^_`{|}~=) . Close Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number, and one special chara … input more than 0 characters your New Password may not display properly Cancel Submit Email Address Not Found Please go to My Profile and add an email address to continue with this action. Cancel
%PDF-1.6 %���� 1495 0 obj > endobj 1528 0 obj >/Filter/FlateDecode/ID[ ]/Index[1495 66]/Info 1494 0 R/Length 140/Prev 10853425/Root 1496 0 R/Size 1561/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�$�I0[ Dr���. �ILf�I �x�-&��I^$0�L���� ��D���H�6)�DjIF�E`���b��s@$�>�� >stream h��}Pwǟ�MBBI���jb%g�R��5�K��vB �Z`���� �Z��`řH}���/h}��� -�)�7�'M v쩵R�+�^�v7�z7ӛ�����$���{���ͳ;� (uC@h!H��Cl*�n��ϧ�$�In�!+B F��U,�(�D�J����z���vS����>�o� �V��TJh���V��)c�I��y��C9�vA���ēx�y��7�ة���?;&; G���J�=i� [��f�|��U��m��xC�z7_��=�u���}���.3��]�=�[Szq����v�c���� [vO�e� … }yn-6���{�wz`����֜a�����7������ '_ pV�� endstream endobj 1523 0 obj >stream application/postscript Greg Nielsen SBT-Logo-TM-4c-pos.eps Adobe Illustrator CS2 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 uuid:24EBF3E16E8511DA9E4086E538E29E18 uuid:24EBF3E26E8511DA9E4086E538E29E18 endstream endobj 1524 0 obj >>>/Subtype/Form/Type/XObject>>stream H�2P��*�2PAC�l.}�`��b.#=Cs#=#s csC= ] ��H�(�+�+� �n� endstream endobj 1525 0 obj >/ProcSe … ����J�`� �L|0�@��#���24��[w���AX������ �u� endstream endobj 3 0 obj >stream application/pdf LONZA_LOGO_MAIN-BLK 2021-01-28T18:30:46Z 2021-01-28T18:30:46Z 2021-01-28T18:30:46+01:00 Adobe Illustrator 25.1 (Windows) uuid:a3de2334-99ae-43ee-9bbd-741f79caa74a xmp.did:4b30f76e-9211-bb47-ab33-a3600ddfe9ba uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9963990e-1bd9-b545-9ca6-06946215f430 xmp.did:9963990e-1bd9-b545-9ca6-06946215f430 uuid:5D20892493BFDB11914A8590D31508C8 … 6215f430 2021-01-28T18:06:09Z Adobe Illustrator 25.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4b30f76e-9211-bb47-ab33-a3600ddfe9ba 2021-01-28T18:13:17Z Adobe Illustrator 25.1 (Windows) / Print AIRobin Document False False 1 134.166337 51.249506 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 29 29 27 CMYK Red RGB PROCESS 227 6 19 CMYK Yellow RGB PROCESS 255 … ) 2024-01-31T09:39:48+01:00 2024-04-10T08:57:56+02:00 2024-04-10T08:57:56+02:00 application/vnd.adobe.photoshop 4 Coated FOGRA39 (ISO 12647-2:2004) xmp.iid:c6d133e2-6c37-4c43-a5c7-2d2003c911c9 adobe:docid:photoshop:cbdeaaad-f9b2-a14f-b3b0-3fa9427c4f33 xmp.did:31c8d117-0238-4925-9f3f-74244c25ee44 created xmp.iid:31c8d117-0238-4925-9f3f-74244c25ee4
Instagram Instagram Log In Sign Up Close Never miss a post from whitchurchfolkfestival Sign up for Instagram to stay in the loop. Sign up Log in whitchurchfolkfestival • Follow More options whitchurchfolkfestival 15w Keep an eye 👁️ out for these beauties appearing around the place! 🌸We can hardly believe there are only *8 weeks to go!* until the town throws open its doors and the Whitchurch Folk Festival dances back into town! 🌸The big day is Saturday 9 May 🌸Now in its third year since being revived, the festival has become a firm fixture in the town’s calendar, drawing people from surroun
11th Novalix Conference 'Biophysics in Drug Discovery 2025' - Programme LDO Conferences Home Committees Organising Committee Programme Programme Confirmed Speakers Infomercials Social Programme Book of Abstracts Pictures Registration My Registration Prices & Activities Abstract Submission Abstract Guidelines Accommodation General Terms and Conditions Sponsor-Exhibit Confirmed Exhibitors Infomercials Sponsor-Exhibit Practical Info Prices & Activities Sign up to emails About Novalix Deadlines General Information Previous Editions Venue & Access Conferences > Archives > 11th Novalix Confere
Pioneer Brand Spotlight: L’Oréal at the Forefront of Timeless Skin Sustainability Upcycling Claims Certifications Applications Functions Performance claims Certifications Chemical Groups Regulations Your Monthly Regulations Radar Trends Trending Ingredients Industry trends Conferences & Fairs Packaging Idea to Market Going Global Entering China Entering the US Entering Europe Entering the UK Entering India Distribution models Giveaways Pioneer Brand Spotlight: L’Oréal at the Forefront of Timeless Skin Home Personal-care Pioneer Brand Spotlight: L’Oréal at the Forefront of Timeless Skin Aut … ne, the company is building a network of biotech partnerships. Its BOLD venture fund recently took a stake in Timeline, the Swiss biotech behind Mitopure®, a patented form of Urolithin A shown to boost mitochondrial energy and stimulate collagen synthesis. Timeline’s molecule is one of the first longevity actives to be clinically validated across both wellness and beauty categories. Other strategic collaborations include Senisca , a UK-based lab reversing cell senescence, and
Member News Archives - Knowledge Exchange UK Jobs Board Log In Become a Member Jobs Board Log In Become a Member Home Membership hidden – do not delete Learn & Develop hidden – do not delete Events hidden – do not delete News Resources hidden – do not delete Home Membership Why Join Us? Become a member Members Directory Learn & Develop Book a course In-House Training Workshops Events Conference KE Awards Directors’ Forum Online Events Resources Blog Reports Webinars About About Us Work with us What is Knowledge Exchange? KE Concordat About The 8 Guiding … ties Book onto a training course In-House Training Mentoring Become a volunteer Apply for RTTP Contact Us +44 (0)1223 776130 [email protected] St John's Innovation Centre Cowley Rd, Milton, Cambridge, CB4 0WS Follow Us Content Category: Member News Home > Member News A company borne out of University of Exeter research has raised more than £2 million from existing investors, to take its cell rejuvenation technology to aid healthy ageing to the next stage of development. SENIS … lder base. Existing investors reinvesting in this latest seed round include R42 Fund, Emerging Longevity Ventures, Longevity Tech Fund and Trend Ventures. SENISCA also welcomes on board QantX and APEX Ventures as new investors. “From the beginning we were impressed by the scientific excellence Lorna and the SENISCA team showed” , says Dr Diana Röttger, Principal at APEX Ventures. “SENISCA’s discoveries in cell rejuvenation have a vast potential as they target a large se … seek to nurture.” The £2.15m of cash funds raised supplements the recent award of a £180,000 grant from Innovate UK, the third non-dilutive funding grant that the company has been awarded since incorporation in 2020. SENISCA’s innovation, which restores functional levels of RNA splicing factors (which are essential for cellular responses), takes old or ‘senescent’ cells and effectively resets the cellular ageing clock. This combination of new equity and grant funding a … or medical procedures more quickly. The company has secured a £197k grant from Innovate UK and pre-seed investment of £281k from SFC Capital to develop a range of implantable medical devices that will improve patient quality of life by accelerating healing and recovery after common surgical procedures. 1 The polycarbonate-based
UK Minister visits Exeter spin-out companies, highlights innovation in health, AI, and climate | NIHR Biomedical Research Centre: Exeter posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree … The Auckland Bioengineering Institute has been awarded $4.5m from the Catalyst Fund to partner with the Oden Institute (University of Texas) on physics-informed AI digital twins. Together, researchers will develop physics-informed AI digital twins – advanced computational models that don’t just find patterns in data, but also embed the laws of physics. This makes them far more reliable for complex biological and environmental systems. With the leadership of Professor Merryn … energy-efficient artificial intelligence. The project has received a $2 million grant from the National Science Foundation’s Emerging Frontiers in Research and Innovation (EFRI) program. The funding supports their efforts to study the complex information processing in the brain and replicate it in engineered systems. https://lnkd.in/dw3-X6rK Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Timothy Liljebrunn 9mo Edited Report this post Researchers … make this avaliable for all researchers. We start by helping researchers draft grant applications, but that’s just the beginning. View C2PA information 147 45 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Attila Ulbert, PhD 9mo Edited Report this post Abstract: AI is moving beyond prediction to become a partner in invention. While today’s models excel at interpolating within known data, true discovery requires stepping outside existin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
ISSCA - ISSCA is proud to welcome Jason Pencek, DC, FNP to... Facebook Log In ISSCA's Post ISSCA April 29 · Shared with Public ISSCA is proud to welcome Jason Pencek, DC, FNP to ISSCA 122 in Punta Cana, Dominican Republic. A longevity and regenerative medicine expert, Jason Pencek is recognized for integrating advanced diagnostics, peptide-based therapies, and cellular medicine to redefine performance optimization and long-term health outcomes. His presence reflects the advanced clinical thinking and innovation that continue shaping the future of regenerative medicine at ISSCA. #ISSCA122
%PDF-1.4 %���� 2841 0 obj > endobj xref 2841 284 0000000016 00000 n 0000007157 00000 n 0000007317 00000 n 0000113778 00000 n 0000114489 00000 n 0000115238 00000 n 0000115950 00000 n 0000115989 00000 n 0000116039 00000 n 0000116088 00000 n 0000116139 00000 n 0000116190 00000 n 0000116241 00000 n 0000116290 00000 n 0000116340 00000 n 0000116391 00000 n 0000153155 00000 n 0000194986 00000 n 0000195345 00000 n 0000195634 00000 n 0000236221 00000 n 0000275707 00000 n 0000314473 00000 n 0000356748 00000 n 0000404289 00000 n 0000448118 00000 n 0000940789 00000 n 0000940957 00000 n 0000941015 00000 n … ����!�Kѩ!���c�����j� endstream endobj 2890 0 obj > endobj 2891 0 obj >stream application/postscript Print Dee Smyth 2022-02-15T08:17:05Z 2022-02-15T08:17:05Z 2022-02-15T08:17:05Z Adobe Illustrator 24.3 (Macintosh) xmp.iid:2ada7833-6ef7-437a-8efe-01ee64edc641 xmp.did:2ada7833-6ef7-437a-8efe-01ee64edc641 uuid:5D20892493BFDB11914A8590D31508C8 default uuid:8775739b-9aca-af47-b025-5f003248d9f4 xmp.did:30272f14-dcec-4fa9-ab2e-46a2838034b4 uuid:5D20892493BFDB11914A8590D31508C8 de … Adobe PDF library 10.01 endstream endobj 2892 0 obj > endobj 2893 0 obj >stream application/pdf DSIT_Lesser_Arms_Stacked_Black Department for Science Innovation & Technology Department for Science, Innovation & Technology logo Department for Science Innovation & Technology stacked logo 2024-10-02T10:30:01+01:00 2024-10-02T10:30:01+01:00 2024-10-02T10:30:01+01:00 Adobe Illustrator 28.0 (Macintosh) uuid:2091124f-0972-0b49-952b-df5270130ef9 xmp.did:d2581542-eae1-4a79 … ry 17.00 DSIT Design102 endstream endobj 2894 0 obj > endobj 2895 0 obj >stream application/postscript Web (Nikki Prosser) Adobe Illustrator 25.2 (Macintosh) 2021-03-30T14:51:06+01:00 2021-03-30T14:51:06+01:00 2021-03-30T14:51:06+01:00 default uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:909c8ddb-9a9a-44f5-9cd7-6737e349d128 xmp.iid:909c8ddb-9a9a-44f5-9cd7-6737e349d128 xmp.iid:be342c15-ff6e-48af-8180-5253b5bdf5e4 xmp.did:be342c15-ff6e-48af-8180-5253b5bdf5e4 uuid:65E6390686CF1 … 0bb33e 2021-02-09T19:59:36Z Adobe Illustrator 25.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:7d748073-1508-4e80-870f-ecdda8726d87 2021-03-29T17:06:52+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:17253
Program – Swiss RNA Therapeutics Summit Skip to content Swiss RNA Therapeutics Summit Uniting Leaders and Talents in RNA Therapeutics Program Speakers & Panelists Registration Venue Sponsors Organizers News Mailing List History & Previous Editions Menu Search for: Program Preliminary Program. Subject to Changes & Updates. Time Session 08:00 Welcome Coffee 08:45 Opening Remarks – Organizers 08:50 Keynote I: Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech – “mRNA vaccines for the treatment of cancer” 09:30 Company Presentations
%PDF-1.7 %���� 1 0 obj >/Metadata 4526 0 R/ViewerPreferences 4527 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��V[o�6~7��p���)�DI@�Υ����E ����6Y������P�l-Zզ ȼ��}�J���E6M����G�ÀQ���k�b��n��;Xu;��Q�m��aV 3͙ j��w�ί��ZT� ��ҿ� �����M��T��,� ��v*bT�F\��~��eӥ5f�LfF��\~�e�E���>��uQ����������,[%E�^���s�Kw�ua�f�XC cKǁ O1h"�X1 �T�x�!����.j �w;��>���n�v� %�7��qV*R��2�BI�"���Rg�Ԩ�� j�IV��?$���=�����y�T�M�hh=ZQ%����ज़ =c > e … $ �9l��s� �$�HK˻y5Kw��]�i�d�luݼ�y��[� K{����bA�I�9 ��l-�C���J� �m} ��RFP�wJv�; ���s��p�I#�������h# �"�>?�r:{Q?����j��h� ��L�`WX��x ���x�� c�X� ����;`�`$&[���g �� ��=�@�H* r��'�-�sӡ錠6�V��H�p:�8��ۧl , �F�t�}8� {t��7� �`3�t g �c���B�-� �q���ӯ@~i8c�����z�{`s�*�;����C����u�O x�A9-�v�$�^��q�Ҋ:��n L�_��q�ۭE(*+��1�1�}�z ֆ�͐r�P���\�� �N>olsU&]ȥF`'�)sϦ3�q�1�k"�A�� a�z�q�sV�[�Ǥ�3�r��}� sB�~�S��l�|����G�������|��?��S���p>V?�`3��=� íQ�w � 1�����
CARINA Network cross-sector meeting | British Society for Immunology Skip to main content join now login Main navigation Membership Join the Society Frequently Asked Questions Manage your membership Grants & prizes Membership categories Careers BSI careers support BSI jobs board Funding opportunities BSI Careers Review Guides and resources Resources for educators Studying immunology Events BSI Congress BSI Events BSI-CIPN Conference Past events mRNA technology webinars Sponsor our events Grants to support you Training Bioinformatics Flow cytometry Foundations of immunology Immunology nursi … y 2024 CARINA Network meeting June 2022 CARINA Network Early Career Development Application Guidance Notes Connect Immune Research EFIS Vaccine Task Force National Core Studies Immunity STRAVINSKY UK Coronavirus Immunology Consortium British Society for Immunology 9 Appold Street, London, EC2A 2AP E: [email protected] T: +44 (0)20 3019 5901 Cookies Policy Privacy and Security Policy Registered charity - 1043255 in England and Wales / SC047367 in Scotland, and registered in E
Award-winning partnerships shed light on thriving innovation ecosystem in the South-West - University of Exeter News Skip to content University home Study Research Business Alumni and supporters Our departments About us Contact Press Office University of Exeter News Primary Menu University of Exeter News Home University news Corporate Exeter campuses Cornwall campuses Student news Research news Arts & Culture Business & Economy Environment Family & Education Health Politics & Society Science Sport Tech Exeter Innovation All news categories Videos Events Search for: Home Univers … r Innovation All news categories Videos Events Search for: Home University news Award-winning partnerships shed light on thriving innovation ecosystem in the South-West Exeter Innovation Top stories University news Award-winning partnerships shed light on thriving innovation ecosystem in the South-West October 4, 2024 Ben Dickenson Bampton Nine flagship projects have won awards for their outstanding contribution to society, sustainability and health at the Knowledge Exchange … e Possible’ , delivered at COP28 in Dubai and winner of the Sustainable Futures Award, pioneered a new way of engaging people with climate science through powerful storytelling, poems and performances. Involving a network of global partners – from the Met Office and British Embassy to the American University in Cairo and the Emirates Literature Foundation – the University of Exeter-led project reached 28 million people with its message of resilience and hope. Global Carbon Bu … change Team of the Year We Are the Possible: Winners of the Sustainable Futures Award Tied in first place for ‘Knowledge Exchange Team of the Year’ were two equally impressive climate projects. One of these was Global Carbon Budget , which mobilises leading climate scientists and international partners to report on the world’s annual carbon emissions, influencing climate talks at the highest level – including meetings with the UN General Secretary. The other, the 3 rd C … and wellbeing. Trailblazing spin-out company SENISCA won the ‘Commercialisation Award’ for their anti-ageing technology, which restores cells to a younger functional state and is being used to advance drug treatments. Strong competition meant that two projects took home the ‘Health, Wellbeing and Life Sciences Award’. The first, ENLIVEN , revolut
Cambridge Antibody Technology - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 09 Dec 2025 Cambridge Antibody Technology Private Company | 1989 | United Kingdom | 250-500 | www.cambridgeantibody.com Private Company | 1989 | United Kingdom | 250-500 | www.cambridgeantibody.com Last update 09 Dec 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Digestive System Disorders Respiratory Diseases Monoclonal antibody Disease domain score A glimpse int … Ltd. and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN). Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei. He was also formerly Chairman of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006. Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chis … iliumChris Welsh, Evi [email protected] About SENISCA SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple ph … sly co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. The company is currently developing its KnotBody pipeline, including candidates with significant potential to be first-in-class and best-in-class therapeutics. For more information, visit Logo - SOURCE Maxion Therapeutics Executive Change 100 Deals associated with Cambridge Antibody Technology Login to view more data 100 Translation … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
Ageing research to tackle long-term sickness Loading... UK Day One UK Day One Health Science Research Share Link Copied! Download PDF Ageing research to tackle long-term sickness As Britain continues to age, our multimorbidity problem will worsen. Alongside public health measures, ageing research could help tackle the drag of long-term sickness on our economy, with the greatest benefits in the most deprived areas. August 23, 2024 Sanjush Dalmia Tina Woods Table of Contents 1 . Summary 2 . The Challenge 3 . The Opportunity 4 . Plan of Action 5 . FAQ 6 . Authors Table of Contents 1 . Summary 2 . … iety for Research on Ageing. Research Updates Stay up to date with our research Submit Contact Us For more information about our initiative, partnerships, or support, get in touch with us at: [email protected] Research Updates Stay up to date with our research Submit Contact Us For more information about our initiative, partnerships, or support, get in touch with us at: [email protected] © Centre for British Progress 2025 Privacy Policy Cookie Policy Terms and Condi
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
R42 Group – Info, Investments & Portfolio Industries Apps → AI → BioTech → Fintech → Software → SaaS → MarTech → LegalTech → E-Commerce → Stages Early Stage → Pre-Seed → Seed → Series A → Series B → Countries Denmark → Finland → France → Germany → Sweden → United Kingdom → United States → Cities Amsterdam → Berlin → Boston → Copenhagen → London → Los Angeles → Miami → Munich → New York → Paris → San Francisco → Seattle → Silicon Valley → Stockholm → Find investors on Gilion Industries Apps AI Biotech Fintech Software SaaS Martech Legaltech E-commerce Countries Denmark Finland France German … ; R42 Group R42 Group 2004 Founded 15 Investments United States Offices Venture Fund Investor Type About the firm R42 Group is a venture capital firm specializing in deep science ventures, focusing on AI, biotechnology, and technology sectors. Established from Dr. Ronjon Nag's family office, the firm leverages his extensive experience in AI and entrepreneurship to support early-stage companies. Dr. Nag has co-founded and advised companies that were acquired by Motorola,
#copdawareness #copd #ageing #biotech | SENISCA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
Beauty at the heart of longevity L'Oréal Groupe | L'Oréal Finance Skip to main content COURS € 387.95 +0.34% CAC 40 8431.61 +0.56% Search en fr en fr Share price Financial calendar Individual Shareholders Become a shareholder Loyalty Bonus and Registered Shares Annual General Meeting Shareholder events The Letters to shareholders Consultation committee Frequently asked questions Investors & Analysts Results hub Strategic presentations Regulated informations ESG In the heart of L’Oréal News L’Oréal at a glance Governance Annual Report Universal Registration Document Disconnect New … ual property portfolio. In 2024, L’Oréal, through its strategic venture capital fund, BOLD, acquired a minority stake in Timeline. Timeline was very recently named a Milestone 1 award winner for the largest and most prestigious Longevity prize called the XPRIZE Healthspan competition. • Bio-actives: A strategic partnership with biotech, Veminsyn will help discover, develop and scale innovative longevity bio-actives and cosmetic ingredients with low-carbon biomanufacturing. Wi … earch Agreement partnerships Senisca: A multi-year R&D partnership with the award-winning biotech company, Senisca, will harness their expertise and proprietary technology to reprogram aged ‘senescent’ cells, which behave differently to young, healthy cells and are a crucial aspect of longevity. With ongoing collaborations with longevity leading experts • Dr. Andrea Maier of the National University of Singapore (NUS) on the interplay between the skin and internal organs.
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
SENISCA partners with L'Oréal on healthy ageing research | Innovate UK ICURe posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … tral to global, consumer-impacting applications. 🔬 About SENISCA SENISCA is an award-winning biotech company developing RNA-based senotherapeutics that reverse cellular ageing. Their innovation targets dysregulated RNA splicing, a newly identified hallmark of ageing, with the aim of restoring cell health and treating age-related disease. Ben Lee , now Co-Founder and Head of Discovery Research, completed ICURe Explore in 2020. Later that year, the company was founded. We look … months, starting on October 1, 2025, and concluding on September 30, 2026. This award reflects NSF's commitment to supporting projects with significant intellectual merit and broader impacts. #Innovation #Healthcare #SBIR #STTR #Biotechnology Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Censo Biotechnologies (Axol Bioscience Ltd.) 2,297 followers 8mo Report this post Yesterday, our team attended the UK Organ-on-a-Chip (OOC) Symposium, where th … s pleased to announce that the company has received a $2.2 Million Phase II NIH Grant to further develop the minimally invasive use of TETRANITE® to treat complex spine fractures. This grant will advance the company’s preclinical research to demonstrate an improvement to the current standard of care for treating vertebral compression fractures. RevBio would especially like to recognize Brittany McDonough , Director of Product and Clinical Development, for leading the preclini … is important use of TETRANITE. Under her leadership, funding from this critical grant will significantly propel the company’s spine program forward. To learn more about this grant and TETRANITE’s spine indication, read the full press release, here: https://lnkd.in/gZiYwtP7 The National Institutes of Health #RevBio #TETRANITE #TransformingBoneRepa
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
Empirical Ventures secures £10M from the British Business Bank Skip to content Toggle Navigation News Events TNW Conference June 19 & 20, 2025 All events Newsletters Partner with us Jobs Contact News Latest Deep tech Sustainability Ecosystems Data and security Fintech and ecommerce Future of work Conference media hub More Startups and technology Investors and funding Government and policy Corporates and innovation Podcast This article was published on March 31, 2026 Investors and funding Empirical Ventures secures £10M from the British Business Bank to back UK ‘venture scientists March 31, … , taking total support to £15M. Empirical Ventures , the Bristol-based deeptech fund co-founded by two scientists-turned-investors, has secured a £10 million commitment from the British Business Bank through its Regional Angels Programme, bringing the Bank’s total support for the firm to £15 million. The first £5 million was committed in April 2024. The new capital will allow Empirical to write larger cheques to early-stage science-led founders across the UK, particularly out … led founders across the UK, particularly outside London, using its SEIS and EIS fund alongside an angel syndicate. The firm was founded by Dr Ben Miles (PhD, Physics) and Dr Johnathan Matlock (PhD, Chemistry), who first worked together at Ziylo Ltd, a University of Bristol spinout developing glucose-sensing molecules for diabetes treatment. In 2018, Novo Nordisk acquired Ziylo in a deal potentially worth over $800 million, one of the largest acquisitions of a UK spinout at th … e navigating the transition from academic research to commercial operation. The fund targets pre-seed and seed rounds in energy, advanced materials , robotics, and life sciences, writing high-conviction cheques and taking board seats. Portfolio companies include Quantum Dice, Wave Photonics, Senisca, Forefront RF, Zero Point Motion, Scarlet Therapeutics, Lumi Industries, and Intrinsic Semiconductor Technologies. Mark Barry, Senior Investment Director at the British Business B … ping a wild ride from crypto mining to AI darling 4 Thena Capital closes a £45M fund to back UK medtech, a first for an all-female GP team 5 Humanoid robot maker EngineAI files for a Hong Kong IPO Related Articles apple Why Apple built a third-party AI system for Siri and then refused to show it at WWDC anthropic Anthropic’s model shutdown just h
If they could turn back time: how tech billionaires are trying to reverse the ageing process | Ageing | The Guardian Skip to main content Skip to navigation Close dialogue 1 / 3 Next image Previous image Toggle caption Print subscriptions Search jobs Sign in Eur Europe edition UK edition US edition Australia edition International edition The Guardian - Back to home The Guardian News Opinion Sport Culture Lifestyle Show more Hide expanded menu News View all News World news World Cup 2026 UK news Climate crisis Ukraine Environment Science Global development Football Tech Business Obituaries Opin … t seems pretty egocentric while we still have malaria and TB for rich people to fund things so they can live longer,” he told an “ask me anything” forum on Reddit . Perhaps the motivation doesn’t matter. Lord says: “We’ve got an ageing population, but we are living longer without living healthier. If you are going to do something with your squillions, it’s as good a target as any.” Prof Lorna Harries, a molecular geneticist at the University of Exeter’s medical school, agrees … for dementia, a huge public health problem, which you can then turn around and apply to cardiovascular disease, or stroke, or osteoarthritis, that is going to make someone a lot of money,” says Harries, who is also the director and co-founder of Senisca , a biotech spin-off of the University of Exeter that is developing “senotherapeutics” to reverse senescence. There are no guarantees of success, of course, but that is the nature of medical research. “What excites me about A
LifeSpan Ventures Portfolio Companies & Investment Focus | InvestorMatch.pro Investor Match How It Works Pricing Explore Investors For Investors Blog About VC Firms LifeSpan Ventures LI LifeSpan Ventures VC Boston, MA Website How to approach: warm intro preferred Start a Campaign Explore Similar Investors Stage Seed Check Size $1.0M – $3.0M Portfolio 23+ companies Team 1 partner Investor activity Investments in last 12 months: 0 Investment Thesis Focuses on HealthTech innovations improving the quality of life for seniors and healthcare efficiency. Meet the Team AD Alice Drummond GP HealthT
#innovationinvestment #universityspinouts #venturecapital #impactinvesting #deeptech #healthtech #sustainability #regionalgrowth | Richard Haycock LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By c … . Yesterday also marked two significant milestones: the opening of our 2025 EIS Fund and the official launch of our fundraising for our new £300m investment vehicle. This expansion represents a pivotal opportunity to scale our impact and address the £1bn+ investment opportunity we've identified in the region. The journey of turning scientific breakthroughs into commercial success requires patient capital, deep expertise, and strong partnerships. We're privileged to be playing … ncial returns and meaningful impact. Particular thanks to our panel members Tom Grant, CFA at Aviva , Veronica Humble at NatWest Cushon and Michele Barbour Here's to the next chapter of innovation-led growth in the South & Southwest! 🚀 #InnovationInvestment #UniversitySpinouts #VentureCapital #ImpactInvesting #DeepTech #HealthTech #Sustainability #RegionalGrowth 112 1 Comment Like Comment Share Copy LinkedIn Facebook X Sarah Cole 1y Report this comment Richard Haycock an
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
%PDF-1.7 %���� 1 0 obj >/Metadata 123 0 R/ViewerPreferences 124 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.75 841] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]Ys9�~w���v� �\8��p��n���z��{ (�:�%�#R�5�~� ȪB�lU���H���8_ H�|}��:��7���z�z���/g��_�,W�zy�Z��yvqu;�\-o_~�?���o���ݫW�7��N���Y���K9�'E�����ZL�ϟ������goN�?{���999�L����ɚzRUUV�on�M�?V���y���~����ϟ�~4��kr�ϟ}m ���g����FǤ�3Y�[ͽUYf��LZ��,M�����%Ѫo����n�o�� O�z���d�%�ڊ��_�iĿ44U�dҌ��γBN�6�#��*�h����a0~��],���[N��������C�y& … 7��ӿ��� ,ϸ�� {��� ��yn�9�g#�ُ\�2�E7�x�dc��Y�� ���-�/ ��)y�����?u�;v��ks� \rfp����jo�tI�]��;�.�|�؆ꮷ��^�7se{��>ۋ��:M��{Q�s���o��69&��_~�[��p�W��:�e��/���i喚��W�~X�\���?nK��a�������u8N] {�Z��;��/oL���v٧w �GVqo��%�u�w����N��n���#���n��e�ٌz���U�rg(m�l�M7ᅹ^��D�������+ڎ3�ޚ0��S���Mz�t!n�a�O1��T��az/D��N��"H/ҋz����ER � ��4D���@��"EQ � ��8Ν�?�?��g�s��������}��F�*��h�8���� .���l��m�Ťlń�����v��08\\��T��� A�:!!���~������S����t`��`d�1F�X�Zc?
SENISCA Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Aging Treatments SENISCA focuses on developing RNA-based therapeutics targeting cellular senescence, offering opportunities to collaborate with biotech firms, healthcare providers, and pharmaceutical companies interested in anti-aging and age-related disease treatments. Funding and Growth With recent investments totaling over USD 4.7M and grants from Innovate UK, SENISCA has demonstrated strong finan … in the biotech industry. Market Positioning Recognized with the Nature Spinoff Prize and actively developing treatments for conditions like idiopathic pulmonary fibrosis, SENISCA is positioned as an innovative player in the aging and respiratory disease markets, opening doors for strategic partnerships and licensing deals. Expansion Potential Operating within the UK biotech sector with recent funding and product development milestones, SENISCA represents a promising partner … Ventures invests in SENISCA. Oct 23, 2023 | www.prnewswire.com Senisca received award 2022/2023 Nature Spinoff Prize on May 25th '23. 2 5 May 2023: SENISCA, a UK biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the diseases of ageing, today announces that it has been shortlisted for the 2022/2023 Nature Spinoff Prize. May 24, 2023 | www.globenewswire.com Innovate UK invests into Senisca $712K. Senescence-targeting biotech S … . Senescence-targeting biotech SENISCA announced it has been awarded a £571,350 grant from Innovate UK towards the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). May 11, 2023 | longevity.technology Senisca is developing oligonucleotide treatments for idiopathic pulmonary fibrosis. Innovate UK has awarded biotechnology company Senisca £571,350 (about $712,000) to develop oligonucleotide treatments for idiopathic pulmonary
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
%PDF-1.7 %���� 1 0 obj >/Metadata 129 0 R/ViewerPreferences 130 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.75 841] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=�rܶ���?�Qsʢ�/���,ى�I�d��yH��ht][E#��~��W��H{f]����F��h�� /vN�w��8{��܊U܉�ǘm�#@I$Q L�3P�(� Jm]���,���Y��V��0kw��vl8���#;20ٖ"�³�T�� ���b-X[�Y�)�#8/k��4_�,�;J�/� i�>��Fʼnf#�ԭ�ߏ�k c��F4 ��k�c�Ʀ�4¯.hKa4�&�rhc��+>baZ�JF{yn��]��d���n� �ȉ�����x�C�����2�c x ���PU�L;����V�s�|�� ����f !�����N �&M��\���iF
SENISCA SENISCA About Us Scientific Approach The Team News & Events Vacancies Publications Contact Forward thinking to reverse cell ageing Developing a new generation of senotherapeutic interventions to treat age-related disease. Read More About Us SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence. Age-related disease is caused by … ientists, expanding the leadership team, raising both private equity and public grant funding, and producing strong experimental data to support our shared vision of moving SENISCA's technology into the clinic where it will make a real difference to the lives of those affected by chronic age-related disease. Ben Lee I joined Lorna's academic team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, and over the following decade or … I was entrepreneurial lead on our successful Innovate UK-funded ICURe programme application; a 3-month feasibility study to assess the commercial viability of our ideas in the marketplace. SENISCA was officially founded shortly after this, with Lorna as CSO, Kirsty as Launch CEO, and myself as CTO. A large part of my role has been to lead the laboratory team in developing higher-throughput assays and techniques more suitable for a high-growth biotech company, which has allowe … ecutive Officer. Find Out More SENISCA shortlisted for 2022/2023 Nature Spinoff prize. Find Out More Senisca announce the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology. Find Out More SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Find Out More Exeter healthy … sful candidate to thrive in a fast-paced, cutting-edge research environment --> Apply Please send CV's and initial enquiries to addressed to Anna Bennett (SENISCA's business co-ordinator). We look forward greatly to hearing from you. --> Publications Laura R Bramwell, Jack Spencer, Ryan Frankum, Emad Manni & Lorna W Harries . "Image analysis usin
Welcome Dr Alice Ghidini! Meet our new VP of Oligotherapeutics Development She has over 13 years of experience in RNA therapeutics, having trained in the labs of leading pioneers of the field… | SENISCA | 25 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices a … tech settings (Sixfold Bioscience), where she was awarded a UKRI Future Leaders Fellowship for her work in oligonucleotide delivery design. Super excited for SENISCA to be guided forward with your expertise. 127 25 Comments Like Comment Share Copy LinkedIn Facebook X SENISCA 1y Report this comment Welcome to the team, Alice! It’s fantastic to have you on board! Like Reply 1 Reaction 2 Reactions balaji babu 1y Report this comment Congratulations Like Reply 1 Rea
%PDF-1.7 %���� 1 0 obj >/Metadata 105 0 R/ViewerPreferences 106 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 23 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][s�F�~w����eB�.�\��ey7���ک}H�B�"NhI @Q�_������my��RL�2�����w��uC���C�����0��us��r�����' >�6'���� ڛ��w������l��������?ϟei��ʲI��ʤJ&�i%��y��_I��?{�����7""�t�a������R-��0iV& >�s}_$W= �\��}���g�̒�����F���Ͼ����� �I%Si%R���t�� nU&�{K%K���������7 ��\�t�$'�@Ɵ�x�dO#�� ���4/��T�Ι -��#kb����5s
SENISCA strengthens board with the appointment of Dr David Chiswell as Chair Home Categories Ingredients Analysis Manufacturing Finance Company News Regulatory Drug Delivery Research & Development Sustainability Pharma 5.0 Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Manufacturing Chemist Home Careers SENISCA strengthens board with the appointment of Dr David Chiswell as Chair SENISCA strengthens board with the appointment of Dr David Chiswell as Chair Highly experienced biotech veteran to support SENISCA’s rapid devel … ogen and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund. Dr Chiswell has served as the Chair of the Board of various biotechnology companies including Albireo, Arrow and Sosei. He was also formerly Chair of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006. Dr Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr Chiswell to our Board at
SENISCA raises £2 million in latest seed funding round Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics doses fir... AnHorn’ … lder base. Existing investors reinvesting in this latest seed round include R42 Fund, Emerging Longevity Ventures, Longevity Tech Fund and Trend Ventures. SENISCA also welcomes on board QantX and APEX Ventures as new investors. Longevity.Technology: SENISCA was borne out of research conducted at the University of Exeter; the company has developed a technology to combat and reverse the aesthetic and disease-causing aspects of aging and is aimed at enabling people to live healt … to nurture [ 1 ].” The £2.15m of cash funds raised supplements the recent award of a £180,000 grant from Innovate UK , the third non-dilutive funding grant that the company has been awarded since incorporation in 2020. READ MORE: SENISCA – targeted interventions that boast exquisite specificity SENISCA’s innovation, which restores functional levels of RNA splicing factors (which are essential for cellular responses), takes old or ‘senescent’ cells and effectively resets … effectively resets the cellular aging clock. This combination of new equity and grant funding allows SENISCA to progress its antiaging compounds through to the next phase of ex vivo laboratory tests, as well as expand its management team. The next seed round is scheduled for early 2023 and will seek to raise more than £5 million. Professor Lorna Harries Kirsty Semple, Chief Executive Officer, said: “This latest investment is cementing our place as a global leader in developin … research (and opinions)? Harness’ two-pronged Parkinson’s program secures MJFF grant Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy Perplexity enters the consumer health AI arena Startup targets ‘untreatable blindness’ with bionic eye system Science Corp lands $230m to commercialize vision restor
%PDF-1.7 %���� 1 0 obj >/Metadata 117 0 R/ViewerPreferences 118 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.25 842] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�� �r�6�]U�>� +���������g���8�R3��2�t���d�ş�I��I8�7h��o�r�|��8��B~�> i@�K � ���j���w�h����.7p��O�I�R}��� .�9$K���e$ ;y���� �Bf)vs�s�����!�.���g�[ 3�=� ��p�ڟ��=Ұ����ᔳ�虃^�D��M�C`�Df�qRe��%���v�{� G�`����4� X��S����@�e ����=����{�M~�}N���x!AJ�;��F��Z��J�f=��1��1�p��gD��8G��q��{��|M�y�s��^53 ,x����K����k
Articles | News archive | University of Exeter --> --> Skip to main content Global links University home Study Research Business Alumni and supporters Our departments Visiting us About us News archive Website links News home page News archive Section links Home News archive - 2022 June Articles Articles Senescent primary human skin cells Exeter healthy ageing treatments company raises £2 million in latest seed funding round A company borne out of University of Exeter research has raised more than £2 million from existing investors, to take its cell rejuvenation technology to aid he … lder base. Existing investors reinvesting in this latest seed round include R42 Fund, Emerging Longevity Ventures, Longevity Tech Fund and Trend Ventures. SENISCA also welcomes on board QantX and APEX Ventures as new investors. “From the beginning we were impressed by the scientific excellence Lorna and the SENISCA team showed”, says Dr Diana Röttger, Principal at APEX Ventures. “SENISCA’s discoveries in cell rejuvenation have a vast potential as … seek to nurture." The £2.15m of cash funds raised supplements the recent award of a £180,000 grant from Innovate UK, the third non-dilutive funding grant that the company has been awarded since incorporation in 2020. SENISCA’s innovation, which restores functional levels of RNA splicing factors (which are essential for cellular responses), takes old or ‘senescent’ cells and effectively resets the cellular ageing clock. This combination of new eq … ffectively resets the cellular ageing clock. This combination of new equity and grant funding allows SENISCA to progress its anti-ageing compounds through to the next phase of ex vivo laboratory tests, as well as expand its management team. The next seed round is scheduled for early 2023 and will seek to raise more than £5 million. Kirsty Semple, Chief Executive Officer, said: “This latest investment is cementing our place as a global leader in developing medicine
SENISCA strengthens Board with biotech veteran appointment Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics doses fir... AnH … ogen and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN). As well as serving as Chairman on the boards of various biotechs, including Albireo, Arrow and Sosei, Chiswell was also formerly Chairman of the UK BioIndustry Association, and his contributions to the industry were recognized with the awarding of an OBE in 2006. Dr Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA. His deep kn … research (and opinions)? Harness’ two-pronged Parkinson’s program secures MJFF grant Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy Perplexity enters the consumer health AI arena Startup targets ‘untreatable blindness’ with bionic eye system Science Corp lands $230m to commercialize vision restoration chip MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity Ergothioneine: The little-known molecule tra
SENISCA appoints Tim Edwards as Chair of the Board --> Accessibility: Skip TopNav SENISCA appoints Tim Edwards as Chair of the Board September 10, 2024 02:00 ET | Source: Senisca Ltd Senisca Ltd Life-science leader with 30 years of experience to guide SENISCA towards becoming a clinical stage novel senotherapeutics company Exeter, UK — 10 September 2024: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to target cellular senescence and treat age-related disease, today announces the appointment of Tim Edwards as Chair of the Board. He succeeds Dr. David Chiswell … ris Welsh, Evi Useh chris.welsh @ icrhealthcare.com About SENISCA SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat conditions of ageing. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple p
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
LifeSpan Vision Ventures Invests in SENISCA Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview Trending … rcially astute management team. We look forward to tracking the development and application of their senotherapeutic platform." Dr Sarah Cole , CEO of SENISCA, commented: "We are delighted to welcome LifeSpan Vision Ventures to SENISCA. The fund's deep understanding of science and technology and focus on collaboration, synergises with our mission to be a world-leader in the development of novel senotherapeutics that target the ageing process to treat age-related disease. We l … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
%PDF-1.7 %���� 1 0 obj >/Metadata 118 0 R/ViewerPreferences 119 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]oo�8�_��A/�C��EI�"@�m{������{{��^(���X~,;m>�~ћ��%��Xj�4I��!9��͐����Vwe� ������^�_|l6������/�Y.W�r�j� ��;L�[].���ep��M���_Ea���\� ҂��r ����W��%X�~u�����w,`q����+E����ad9 � ���8`� v�z:q_0�,O㌆�sݮ�B�*b���E9�E(xQ�* �� �e]�5�4����sbm�"�"wM�4,$�2KS������%5���)�H�7�D?��e0���~��l:��sLwgD� ���������y:�~~
Healthcare Archives - QantX Home Invest Team Strategy Portfolio News Contact Investor Portal Select Page SENISCA: treating age-related diseases with ground-breaking science by Hannah Beatrice | Dec 12, 2024 | Healthcare , Innovation SENISCA was born out of more than 18 years of academic research led by Lorna Harries at the University of Exeter, where Lorna still works as both a Professor of Molecular Genetics and as Founder and CSO of SENISCA. Her research uncovered brand new scientific... Lutra Health: integrating community and hospital eyecare by Hannah Beatrice | Nov 27, 2024 | Healthcare , … nd hospital eyecare by Hannah Beatrice | Nov 27, 2024 | Healthcare , Innovation Prize Lutra Health is a software product connecting optometrists with eye surgeons and patients, allowing more patients to get access to the eye care they need in the community without having to visit a hospital. We met co-founder Charles Solanki to hear his story. Charles... QantX Spearheads £3m Investment for Innovative Cancer Screening Technology by Harry | Oct 8, 2024 | Healthcare , Portfolio … ured £3m in funding, with investment led by QantX alongside a substantial £2.5m grant from the National Institute for Health and Care Research (NIHR). This investment marks a pivotal advancement in cutting-edge tumour detection methods. Dr. Andy... Beyond the Golden Triangle by Harry | Sep 12, 2023 | Climate , Healthcare , Innovation Last week, our second annual Investor Showcase Day welcomed nearly 100 founders, investors, advisors, and startup ecosystem pioneers. We were de … in Capital Partners LLP (FRN: 656789). Kin Capital Partners LLP (trading as Kin Fund Services) is authorised and regulated by the Financial Conduct Authority. © 2022 QantX. All rights reserved. Cookie Policy | Privacy Policy We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok Privacy policy
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account September 10, 2024 02:00 ET | Source: Senisca Ltd SENISCA appoints Tim Edwards as Chair of the Board Life-science leader with 30 years of experience to guide SENISCA towards becoming a clinical stage novel senotherapeutics company Exeter, UK — 10 September 2024: SENISCA SENISCA, a biotechnology... March 18, 2024 03:00 ET | Source: Senisca Ltd SENISCA secures additional £3.7 million financing to su … 03:00 ET | Source: Senisca Ltd SENISCA shortlisted for 2022/2023 Nature Spinoff prize SENISCA shortlisted for 2022/2023 Nature Spinoff prize Exeter, UK – 25 May 2023: SENISCA, a UK biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the...
Lorna Harries on SENISCA's Longevity Research | Allan Weiner posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
Video - Healthspan Action Home About About Us Leadership Quotes & Comments Policy HSAC Internship Why Join HSAC The Coaltion View the Coalition HSAC Updates Hawaii Healthspan Corridor News & Video Newsletters News Podcasts Intern Articles Video Events Upcoming Events Past Conference List Resources Boost Your Healthspan Consumer Smart Guide Contact Donate Now Home About About Us Leadership Quotes & Comments Policy HSAC Internship Why Join HSAC The Coaltion View the Coalition HSAC Updates Hawaii Healthspan Corridor News & Video Newsletters News Podcasts Intern Articles Video
SENISCA Archives - SETsquared --> --> --> --> --> --> --> --> Are you an Entrepreneur? Are you a Student? Are you a Researcher? Incubation & Acceleration Centres Investors & Corporates Innovation Hub Deal Readiness Toolkit Partnership opportunities Support Programmes Investment Futures 2026 Investment Futures Spotlight: Life Sciences Investment Futures Showcase Investment Futures: Company Application Entrepreneurs Workout Student Enterprise ICURe Cyber Invest Cyber Investment Report GW-SHIFT Training Research Impact Training: Hydrogen Hydrogen Ecosystem Builder Hydrogen Webinar Serie … potlight: Life Sciences Investment Futures Showcase Investment Futures: Company Application Entrepreneurs Workout Student Enterprise ICURe Cyber Invest Cyber Investment Report GW-SHIFT Training Research Impact Training: Hydrogen Hydrogen Ecosystem Builder Hydrogen Webinar Series Opportunities in Hydrogen Mobility IMPACT-IP Training Investor Partnerships Future Economy Programme Past Programmes SpinOutWest Hydrogen & Sustainable Transport Economy Accelerator IMPACT-IP Pro … es News Podcast Report /News Anti-ageing technology scoops prestigious clinical award SETsquared Exeter and Scale-Up member, SENISCA, has won the ‘Best Start-Up Biotech Company’ award at the OBN Awards 2021. The... /News SENISCA secures £1.3m investment for pioneering anti-ageing technology SETsquared Scale-Up member SENISCA has developed a technology to combat and reverse the aesthetic and disease-causing aspects of ageing, aimed... SETsquared is a partnership between A worl … ures ’25 Support Programmes Privacy Policy Terms and Conditions Follow Us Apply for one of our programmes View all © 2003-2026 SETsquared comprises of the universities of Bath, Bristol, Cardiff, Exeter, Southampton and Surrey. Made by - We are using cookies to give you the best experience on our website. You can find out more about which cookies we are using or switch them off in settings . Accept Reject Settings Close GDPR Cookie Settings Privacy Overview Strictly
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Podcast – SENESCENT CELLS – An Important Target for Diseases of Aging - World Stem Cell Summit About WSCS About Us 2026 Regenerative Medicine Essentials Course Past WSCS Speakers WSCS Public Day (2023) Effective Patient Advocacy Symposium Intersection of RegMed & Healthspan Regenerative Medicine & the Commercial Space Economy Hot Topics in 2023 at World Stem Cell Summit Partners/Sponsors Partners/Sponsors Sponsorship Opportunities Upcoming Events News & Media News and Opinions WSCS 2023 Photos WSCS Video Contact Us Select Page Podcast – SENESCENT CELLS – An Important
SENISCA – targeted interventions that boast exquisite specificity Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics doses fir
SENISCA's Small Molecule Reduces Senescence in Aged Cells – Best Short Oral at Skin Challenges 2024 - Skin Aging & Challenges 2026 Skip to content Home Welcome note Scientific Committee Agenda Tracks Abstracts Submission Registration Venue Replay & Abstracts Conference 2025 Conference 2024 Previous Conferences Skin Ageing & Challenges 2025 Agenda 2025 Speakers 2025 Attendees 2025 Awards 2025 Replay & Abstracts Book Skin Ageing & Challenges 2024 Agenda 2024 Speakers 2024 Attendees 2024 Awards 2024 Replay & Abstracts Book Skin Ageing & Challenges 2023 Agend … Adam Clauss from SENISCA Ltd, UK, for winning the Best Short Oral Presentation Award at Skin Ageing & Challenges 2024! […] November 6, 2024 1 min read Congratulations to Adam Clauss from SENISCA Ltd, UK, for winning the Best Short Oral Presentation Award at Skin Ageing & Challenges 2024! His groundbreaking research, “A Groundbreaking Intervention Effectively Reduces Senescence in Old Primary Cells by Targeting a New Hallmark of Ageing,” highlights … Reductase 1 Activates NRF2 Pathway” Wins Skin Challenges 2024 Best Poster Award (2) November 6, 2024 1 min read “Decellularized Human Umbilical Cord Extracts Enhance Fibroblast Activity” Skin Challenges 2024 Best Poster Award November 6, 2024 1 min read Skin Ageing & Challenges 2026 Welcome note Agenda Abstracts Submission Registration Press Releases Newsletter Archives Contact Kanaya Bldg 4F, 4-11-3, Hatchobori Chuo-ku 104-0032 Tokyo – Japan Follow us
Biotech Startup SENISCA Develops a RNA Splicing Approach to the Treatment of Aging – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help &raqu … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room | Resources | About Read our terms and conditions and privacy poli
Podcast – SENESCENT CELLS – An Important Target for Diseases of Aging | Regenerative Medicine Foundation Leadership What We Do Our Event History Policy Advocacy Education & Outreach Events Upcoming Events Past Events World Stem Cell Summit Regenerative Medicine and Stem Cell Action Awards Regenerative Medicine Essentials The “Art of Science” Inspires Students Exploring Public Policy: Regenerative Medicine and Cell Therapies Congressional Briefings World Stem Cell Summit – CHINA Membership/Register Membership Amazon SMILE News News Portraits of Hope Video Video Chats Contact Do
%PDF-1.7 %���� 1 0 obj >/Metadata 133 0 R/ViewerPreferences 134 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.75 841] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=�r�8���?ԣj¢��ѡKv �Ǹ[�� ����sp�t�:�����]l�'g[8��jq��? �M�U|Vdv�z�����ݾ}st�����dF�����"��gd�i�5��*�+7� N���F�tv)�j}���7��f���N��훏�u��}�lq���dz��� ����M�p�_��i�[�[Ž�ʸ � �C{�4Һ�9|F ��匓�B��Y����X���t��\5��Yj�sZ��Z��D��_��.��i���ń�11ys{ZHgZ^ E�zJw�w�;;8�[��~=���,?�eq{9�[���y2[� �����-�I� �� #�� �R1#��� %.
#longevity #biotech #ageingresearch #senescence #beyondlongevity… | Daphna Stern LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User
Do you think ageing can be reversed? Here are 12 longevity startups to watch | Sifted Analysis October 10, 2022 Do you think ageing can be reversed? Here are 12 longevity startups to watch The quest to slow down ageing — and have healthier and longer lives — is ongoing. And it’s not just about living to 120 Mimi Billing 8 min read Share Nuritas founder and CEO Nora Khaldi The quest to slow down ageing — and have healthier and longer lives — is ongoing. And it’s not just about living to 120. Some scientific research suggests that in years to come, we will have therapeutics that will help us for … vity VC Apollo Health Ventures, Swiss Korify Capital and US-based Longevitytech Fund Senisca (UK) Founded: 2020 by Lorna Harries, Ben Lee and Kirsty Semple (spinout from University of Exeter) As we age, more and more of our cells stop dividing and become senescent, or "zombie" cells. These cells don’t die but are major contributors to age-related illnesses such as cancer, dementia and cardiovascular disease. Senisca’s treatment rejuvenates these cells. The spinout is developi … ue, UK-based Grosvenor's Wheatsheaf Group, and the European Circular Bioeconomy Fund among others. Biolytica (Switzerland) Founded: 2021 by Rob Konrad Maciejewski and James Raaff There are a lot of companies selling longevity supplements, checking your blood markers and biomarkers and even looking at how your DNA may be working for or against you when it comes to certain age-related diseases. But how do you put all that information together into a longevity package that is ri … ovable and how startups can partner with the tech giant News EIF launches €15bn fund of funds to back 100 growth-stage VCs Mimi Billing Mimi Billing is Sifted's Europe editor, based in Stockholm. She covers the Nordics and can be found on X and LinkedIn # Healthtech # Venture capital # Investor survey Sifted Daily newsletter Weekdays Stay one step ahead with news and experts analysis on what’s happening across startup Europe. Sign up for free Recommended Health unicorn Alan r
Professor Lorna Harries (Senisca): Targeting Senescence Through RNA Splicing in Age-Driven Pulmonary Disease · Zoom · Luma Discover Events Sign In Hosted By Oxford Society of Ageing and Longevity Contact the Host Report Event Tech Professor Lorna Harries (Senisca): Targeting Senescence Through RNA Splicing in Age-Driven Pulmonary Disease Hosted by Oxford Society of Ageing and Longevity Zoom Registration Past Event Welcome! To join the event, please register below. Register You will be asked to verify token ownership with your wallet . About Event Targeting Senescence Through RNA Splicing in
🧬 ATDBio Oligonucleotide Symposium 🧬 Meet our next featured speaker, Professor Lorna Harries. Professor Lorna Harries is the co-founder, director and Chief Scientific Officer at SENISCA Ltd., a… | ATDBio LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
LifeSpan Vision Ventures Invests in SENISCA Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. Advanced Search News in Focus Browse News Releases All Ne … rcially astute management team. We look forward to tracking the development and application of their senotherapeutic platform." Dr Sarah Cole , CEO of SENISCA, commented: "We are delighted to welcome LifeSpan Vision Ventures to SENISCA. The fund's deep understanding of science and technology and focus on collaboration, synergises with our mission to be a world-leader in the development of novel senotherapeutics that target the ageing process to treat age-related disease. We l … arget="_self">my CNW Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform Next Gen Communications Cloud Cision Communications Cloud my CNW 877-269-7890 from 8 AM - 10 PM ET Terms of Use Information Security Policy Site Map Cookie Settings Accessibility Statement Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision co
SENISCA: treating age-related diseases with ground-breaking science - QantX Home Invest Team Strategy Portfolio News Contact Investor Portal Select Page SENISCA: treating age-related diseases with ground-breaking science by Hannah Beatrice | Dec 12, 2024 | Healthcare , Innovation SENISCA was born out of more than 18 years of academic research led by Lorna Harries at the University of Exeter, where Lorna still works as both a Professor of Molecular Genetics and as Founder and CSO of SENISCA. Her research uncovered brand new scientific knowledge, which is now being developed by Lorna and her tea … in Capital Partners LLP (FRN: 656789). Kin Capital Partners LLP (trading as Kin Fund Services) is authorised and regulated by the Financial Conduct Authority. © 2022 QantX. All rights reserved. Cookie Policy | Privacy Policy We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok Privacy policy
Exeter spinout company partners with L’Oreal on research to reprogramme ageing cells - University of Exeter News Skip to content University home Study Research Business Alumni and supporters Our departments About us Contact Press Office University of Exeter News Primary Menu University of Exeter News Home University news Corporate Exeter campuses Cornwall campuses Student news Research news Arts & Culture Business & Economy Environment Family & Education Health Politics & Society Science Sport Tech Exeter Innovation All news categories Videos Events Search for: Home Faculty of … r our skin health. Outside of this partnership, we’re also exploring how we can apply our technology to reduce the negative impacts of age-related diseases such as lung disease.” SENISCA Chief Executive Officer Dr Sarah Cole said: “This exciting partnership serves as an excellent validation of SENISCA’s proprietary technology. Through collaboration, we will deploy world-leading research to expand the repertoire of senescence-targeting interventions.” Tags: Profess
--> GtR Home About this system Release history Contact us 📣 Help Shape the Future of UKRI's Gateway to Research (GtR) We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email [email protected] . Search All Data Advanced Advanced --> Please select the required search fields: ORCID iD --> Project Abstract Project Reference --> Project Title --> Projects … bdingnag: Laying the Foundations for an Engineering Odyssey of Epic Scale EPSRC award to University of Ulster and Pagona Papakonstantinou £19,869 Jan 22 - Mar 22 Developing SENISCA's global network to meet future needs: grant applications, oligonucleotide synthesis, and pharmaceutical partners Innovate UK award to SENISCA LTD and Kirsty Semple £19,858 Jan 22 - Mar 22 Feasibility Study for the Restructuring and Optimisation of dCS’ China … e Restructuring and Optimisation of dCS’ China Distribution Channel Innovate UK award to DATA CONVERSION SYSTEMS LIMITED and David Steven £19,849 Oct 07 - Apr 08 Effects of C-60 fullerenes and carbon nanotubes on marine mussels. NERC award to Plymouth Marine Laboratory and James Readman £19,760 Sep 11 - Apr 12 Human Lymphoma Test Innovate UK award to PREDICTIVE LIFE SCIENCES LIMITED £19,756 Sep 10 - Sep 12 Collaborative Doc … IENCES LIMITED £19,756 Sep 10 - Sep 12 Collaborative Doctoral 2010 Grant - Replicas and Reconstructions: Case Studies in Twentieth-century Art AHRC award to UNIVERSITY COLLEGE LONDON and Briony Fer £19,736 Jul 23 - Mar 24 Efficient measurement of noisy quantum processes for error mitigation Innovate UK award to QUANTINUUM LTD and Cristina Cirstoiu £19,700 Sep 07 - Sep 11 DTG 2007 MRC award to University of Cambridge … rsity of Cambridge £19,676 Aug 12 - Dec 12 3d moulding Innovate UK award to CRAFTY TECH LIMITED and Adrian Marshall £19,543 Mar 23 - Aug 23 Degradation mechanism of Zinergy’s printed zinc-based batteries – A route towards rechargeability Innovate UK award to ZINERGY UK LIMITED and Karolina Spalek &po
#longevity #biotech #drugdiscovery #healthyaging #innovation2026 | Aleks Asenov LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A … game-changer for derm-therapeutics. ✅ Cambrian Bio – That recent $30.8M ARPA-H award is a massive validation for their mTORC1-selective inhibitors. ✅ Senisca – Their innovative work on RNA splicing factors is proving that reversing cellular senescence is moving closer to reality. The industry is transitioning from "fragmented discoveries" to cohesive longevity strategies. The question is no longer if we can slow aging, but which mechanism will reach clinical practice first.
Lifespan News - SENISCA hopes to reduce the harmful... Facebook Log In Lifespan News's Post Lifespan News November 3, 2021 · Shared with Public SENISCA hopes to reduce the harmful secretions of senescent cells. lifespan.io Lorna Harries: “We’re Looking to Reverse Senescence” | Lifespan.io All reactions: 43 4 shares Like Comment
SENISCA LTD overview - Find and update company information - GOV.UK Cookies on Companies House services We use some essential cookies to make our services work. We'd also like to use analytics cookies so we can understand how you use our services and to make improvements. Accept analytics cookies Reject analytics cookies View cookies You've accepted analytics cookies. You can change your cookie settings at any time. Hide this message You've rejected analytics cookies. You can change your cookie settings at any time. Hide this message Cookies on Companies House services We use cookies to make o
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL Athletics Cycling NBA Motorsport MMA Sign in … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3196 +0.0032 +0.24% GBP/EUR 1.1598 +0.0008 +0.07% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,041.60 +32.80 +0.82% ADVERTIS … sease. This is a hugely exciting time for the Company as we further develop and apply our unique platform technology to establish our presence as a leading developer of oligonucleotide senotherapeutics. I am delighted the Board has asked me to lead SENISCA. I look forward to drawing on my experience within the life sciences sector and working alongside Kirsty and the outstanding team, to guide SENISCA through the next stage in its evolution and ensure the Company achieves its … ium Chris Welsh, Evi Useh [email protected] About SENISCA SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple ph
%PDF-1.7 %���� 1 0 obj >/Metadata 118 0 R/ViewerPreferences 119 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.75 841] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][s7�~w���VܲF��\N�Te�Nֻ�Mr������DU,Q%;�� 4n���M�*29���h}�������l�8������rq9���|u���o����g�7w�Ǜ��ɧ��Gs�o������t�����ׯ�6�u]�'�D��jդ�l�x����:�{�����W'߳ ��ׯ�nWO�D��I۶U��Ս~��N�����k�ֹo?�~���d�����_��� ���W�a놓?�MN }}�z|\ݖ���j�H��F7�mY[)�,�q�]���Q4}��Xt�ԕ�!��殚��/��� ��������_M���4��u�m�⚁��)ۦ� >�P��N84 ɋQ`��Q��K �
--> SENISCA Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal Animals Investmen
🧬 RNA Medicine &... - Oxford Society of Ageing and Longevity Facebook Log In Oxford Society of Ageing and Longevity's Post Oxford Society of Ageing and Longevity May 27 at 4:59 PM · Shared with Public RNA Medicine & Cellular Senescence What if we could flip a molecular switch and reverse cellular ageing? That’s exactly what Prof. Lorna Harries is working on. Prof. Harries is the founder of Senisca — a cutting-edge biotech developing oligonucleotide therapies that target splicing factor dysregulation to reprogram senescent cells back toward a functional, youthful state. At this ex
--> About us | harrieslab top of page This website was built on Wix. Create yours today. Get Started Harries' lab: Team RNA Home About us Research Publications Volunteer Studies Spin out Company - SENISCA Animal Free Research Outreach Events Contact More Use tab to navigate through the menu items. ABOUT US Our major research interest focuses on factors that influence gene expression and their impact on human disease. We are particularly interested in mRNA processing (mRNA splicing, differential polyadenylation) and how this may affect disease phenotype. OUR TEAM Show Email L.W.Harries@exet … es (with a focus on Molecular Neuroscience) at the Oguro-Ando Laboratory. I now apply my skills in the Harries Laboratory as a postdoctoral research associate, studying the factors underlying stress-induced cell identity changes in diabetes mellitus and how we can leverage novel antisense oligonucleotide therapies to reverse them. Aysha Al Bulushi PhD Student Show Email [email protected] Mail I completed my BSc in Biotechnology in 2018 from SQU, Sultanate of Oman. Then, I a
SENISCA | Faculty of Health and Life Sciences | University of Exeter Skip to main content Search all Study Studying at Exeter Why choose Exeter? Our campuses Accommodation Student life Careers Funding and scholarships International students Clearing 2026 Levels of study Undergraduate courses Masters courses PhDs and research degrees Online degrees and courses Degree Apprenticeships Professional Education Teacher Training (PGCE) Browse by subject area Come to an Open Day Register your interest Find a course Research Our world-leading research Our research is changing the world - making it green
Lorna Harries, Professor of Molecular Genetics University of Exeter and Co-founder SENISCA - ideaXme -- End of the comment --> Skip to content Watch Discover Multimedia Interviews Books to Move the Human Story Forward™ Articles ideaXme Creators Thought Bites Find a Role to Change the World About ideaXme Rich Connectedness News Team Founder and Creative Director Board Advisors Mentors ideaXme ambassadors ideaXme Collaborators Get involved Contact Us ideaXme ambassador mentor Professor Lorna Harries, ideaXme ambassador ID: 005 Lorna Harries is Professor of Molecular Genetics at the University o
%PDF-1.7 %���� 1 0 obj >/Metadata 65 0 R/ViewerPreferences 66 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 20 0 R 21 0 R] /MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\[o�6~������8aDI�$� @�$�t{�m�C� [q�ږ+9I�{�Gwfx�='M��-Q�p8 ~��(���!�O�������!Y>�+��ӻ|�����>=�O��v�!�w���_x�_i�J��3��r��~|�2��") �q�b�D����)������ ]� �^s�{�������� �}{Nq�F��}s:��u��+ҿ�9>�y��u�=>����{|��ᡭs���9 ��E~8���I_��a�I�(b�t8�=�2�t� �cIy$���&̸�e�6��8�!M��D��ql Z�z�l�u;��3�"�0Q�A
--> Kirsty Semple Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal Animals Inv … ISCA. Kirsty trained as a Management Consultant with KPMG London and is a prize-winning Cell Physiology graduate from Edinburgh University. Visit website: https://www.senisca.com/#the-team/#kirsty kirstysemple See also SENISCA University of Exeter spinout developing senotherapeutic interventions through modulation of dysregulated RNA splicing Details last updated 13-Mar-2021 Kirsty Semple News Exeter's company SENISCA raises £2 million to treat age-relate
SENISCA | Exeter Innovation Let’s work together Menu About us About us Partnerships in focus IP policy Innovation support Recruit and develop talent Business support Work with an expert Our expertise Data science and AI Future and emerging technologies Health, lifesciences and wellbeing Sustainability and environment Creative economy Defence, security and resilience Responsible business Energy Futures and Engineering Insights and impact Green Futures Solutions Let’s work together SENISCA The University of Exeter spin-out company, SENISCA, is developing new anti-ageing therapeutics for th … non-diluting income. SENISCA was also shortlisted for the Nature Spin Off prize last year. This places them securely as front-runners in the development of medicines that target the causes and effects of age-related disease. Professor Lorna Harries, Chief Scientific Officer, said: “From my perspective as founder, I have been grateful to Tori and Exeter Innovation for their support whilst navigating what was unchartered waters for me at the time.” SENISCA is
MLQ.ai | Stocks --> MLQ.ai Market Intelligence AI Analyst News Feed Deep Dives Earnings Reports Earnings Calendar Earnings Transcripts Markets Earnings Calendar --> Startups --> Watchlists All Tools Search --> Chat --> Upgrade to premium Get access to all premium data & tools. Upgrade --> Tools Market Intelligence News Companies Earnings Reports AI Analyst Price Targets Investment Signals Stock Screener Stock Charting Earnings Call Transcripts Technical Analysis --> Investors & Insiders Institutional Investors 13-F Filings Insider Trading Congress Trading Nancy Pelosi Tracker Calendars Earning
GtR Home About this system Release history Contact us 📣 Help Shape the Future of UKRI's Gateway to Research (GtR) We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email [email protected] . Developing SENISCA's global network to meet future needs: grant applications, oligonucleotide synthesis, and pharmaceutical partners Lead Participant: SENISCA LTD … nerships will also provide a solid foundation to bid for collaborative EU-based grant opportunities and open the door to future co-development pharmaceutical partnerships. We will be assigning research tasks to members of the SENISCA team, sub-contracting research to a drug development market specialist, and sourcing a pharmaceutical partnering agency to assist us with our partner search. We also aim to attend at least one networking event/conference in early 2022 (either onl … Reference: 10018782 Research Topic: Unclassified Lead Participant Project Cost Grant Offer SENISCA LTD £28,384 £ 19,869 People ORCID iD Kirsty Semple (Project Manager) Publications The following are buttons which change the sort order, pressing the active button will toggle the sort order Author Name descending (press to sort ascending) Title Publication Date Published 10 25 50 --> --> Data The Data on this website provides information about publications, people, … ; APIs A set of REST API's enable programmatic access to the data. Refer to the application programming interfaces GtR and GtR-2 Contact UKRI Gateway Polaris House Swindon SN2 1ET [email protected] Privacy  | Terms of Use   | OGL Data last updated: 14 Apr 2026  
Senisca Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Senisca Teams Senisca Save Saved Exeter 21 Total Employees Year Founded: 2020 View Website Overview Jobs Offices Is This Your Company? Claim Profile Healthtech Biotech SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and hav
Advising SENISCA on its partnership with L'Oréal About us People Expertise Sectors Technology, media & communications Private wealth Real estate, infrastructure & energy Life sciences & healthcare Aerospace & defence Automotive & mobility Business & professional services Chemicals Consumer & retail Financial institutions & insurance Hotels, hospitality & leisure Logistics & transport Manufacturing & industrials Public services & education Legal services Artificial intelligence Banking & finance Brands & advertising Commercial & consumer contracts Competition, EU & trade Copyright & me
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Visa Sponsors in Exeter, UK | ApplyWave ApplyWave Features Resume Tailoring Match your resume to any job posting Resume Builder Build a professional resume from scratch Job Radar Auto-find new jobs that match your profile Recruiter Finder Find hiring managers and recruiters Job Tracker Track all your applications in one place Interview Ace AI-powered mock interview practice Cover Letters AI cover letters, emails & LinkedIn messages Free Tools ATS check, resume score, and more Chrome Extension Apply smarter right from your browser Get started free Visa Jobs Resources Blog Tips and insights … tep-by-step resume optimization Recruiter Outreach How to reach hiring managers Application Tracking Organize your job search Visa Sponsors Companies sponsoring work visas Get started free Log in Get started free Home / Visa Sponsorship / United Kingdom / Exeter UK City Visa Sponsor Companies in Exeter , UK 194 licensed visa sponsor companies in Exeter . These companies are approved by the UK Home Office to sponsor Skilled Worker visas. 194 Licensed Sponsors 194 Showing Exete … city. Research open positions directly on their careers portal and tailor your application to the academic sector. Prepare evidence of your qualifications and research experience, as these are often required for sponsored university roles in Exeter. Monitor application deadlines and recruitment cycles typical for academic institutions, as university hiring may be seasonal or linked to academic terms. Contact the University of Exeter's human resources or international re … sored roles in Exeter. Keep up to date with changes in UK visa policies as they apply to education sector sponsorships, to ensure your application meets current requirements. Network with current or former University of Exeter staff to gain insights into the recruitment process and campus culture. Frequently Asked Questions — Visa Sponsorship in Exeter Which employers in Exeter are most active in providing visa sponsorship? According to the latest data, the University of Exet … nsorship openings Only from verified visa sponsors Instant alerts — be first to apply Filter by salary, location, remote Set up Job Radar (free) → Find recruiters hiring for Exeter roles Get direct access to hiring managers and recruiters — emails, LinkedIn profiles, and job titles. A Talent Acquisition Lead Email LinkedIn R Senior Recruiter Emai
Senisca partners with L'Oreal to reprogram cells | Ronjon Nag posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … NAD⁺ boosters, suggesting effects may be tissue-specific. 💄 #Beauty brands are rolling out #NAD ⁺-powered skincare lines, linking cellular repair with consumer wellness. ⚖️ #Challenges Ahead: While opportunities are vast, there’s a clear need for safety validation, regulatory clarity, and evidence-backed formulations to strengthen adoption and #consumer trust. 🎲 #Explore more Insights@ https://lnkd.in/d33TwCrK #NADplus #AntiAging #LongevityScience #CellularHealth #HealthyAg
SENISCA - Leadership Team | The Org Platform Enrich Pricing Log in Sign up SENISCA Teams Leadership Team Unverified Leadership Team 6 people · 0 jobs The Leadership Team at SENISCA is responsible for guiding the company’s strategic direction and ensuring the effective execution of its mission to revolutionize anti-aging treatments through cutting-edge biotech innovations. They oversee key areas including scientific research, operational management, technical development, business growth, and overall corporate governance, leveraging their collective expertise to drive forward the company’s gr
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic | Gut Skip to main content Intended for healthcare professionals Subscribe Log In More Log in via Institution Log in via OpenAthens Log in via BSG Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * Forgot your log in details? Register a new account? Forgot your user name or password? Basket Search More Search for this keyword Advanced search CME/CPD Latest content Current issue Ar … ndent review committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be directed to [email protected]; to gain access data requestors will need to sign a data access agreement. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercia … ntrations. We visualised durability of antibody responses by calculating 15-day rolling geometric mean anti-S RBD antibody concentrations. Anti-S RBD antibody half-lives were estimated using an exponential model of decay. Linear mixed models were fit using the lme4 and lmerTest package, with biological treatment and vaccine type as fixed effects and each subject as a random effect. CIs were calculated using likelihood ratios. P values for comparison of half-lives were estimat … UK) and Galapagos (Belgium). This study was supported by an NCSi programme UKRI award to RB, DA, NP and TA (MR/W020610/1). None of our funding bodies had any role in study design, data collection or analysis, writing or decision to submit for publication. The sponsor was the Royal Devon and Exeter NHS Foundation Trust. The protocol is available online at https//www.clarityibd.org. The study was registered with the ISRCTN registry, ISRCTN45176516 . Results Patient characterist … 001) ( figure 2 ). Download figure Open in new tab Download powerpoint Figure 2 Rolling geometric mean anti-SARS-CoV-2 spike (anti-S) receptor-binding domain (RBD) antibody concentration over time from the date of the first dose of the SARS-CoV-2 vaccine (week 0) stratified by biological therapy (infliximab vs vedolizumab), vaccine and history of
Hunt UK Visa Sponsors Filters Jobs Log In Hunt UK Visa Sponsors Find jobs from UK licensed visa sponsors — Companies House verified, updated daily. About How does it work Contact Us Find Work Jobs Jobs by Role Register of Licensed Sponsors Visa Types Sponsor Statistics International Student Resources Blog Glossary Occupation Eligibility Income Tax Calculator ILR Tracker Developer API & MCP Sponsorship by Nationality Content on this site is for general information only and does not constitute legal advice. Always consult a regulated UK immigration solicitor for advice specific to your situa … visas has SENISCA LTD issued recently? Where is SENISCA LTD located? How can I apply for a sponsored job at SENISCA LTD ? Is Hunt UK Visa Sponsors affiliated with SENISCA LTD ? Can Hunt UK Visa Sponsors help me get a job or sponsor my visa? How accurate is the information about SENISCA LTD ?
Knowledge Exchange Awards 2026 | Exeter Innovation Let’s work together Menu About us About us Partnerships in focus IP policy Innovation support Recruit and develop talent Business support Work with an expert Our expertise Data science and AI Future and emerging technologies Health, lifesciences and wellbeing Sustainability and environment Creative economy Defence, security and resilience Responsible business Energy Futures and Engineering Insights and impact Green Futures Solutions Let’s work together Welcome to the Knowledge Exchange Awards The Knowledge Exchange Awards celebrate the b … positive change for communities, businesses, and society. In each of the eight award categories, three projects will be shortlisted following review by a panel of senior University staff and external reviewers. All shortlisted nominees and their partner(s) will be invited to attend the awards ceremony on Thursday 15 October 2026 at the Great Hall, Streatham Campus. A huge thank you to everyone who submitted nominations for this year’s Awards. We received more than 100 … the University of Exeter can help your business. Categories Sustainable Futures Award The Sustainable Futures Award recognises excellence in sustainability, environment and life sciences. Potential innovations can include products, policies, services and community partnerships. Shortlisted Projects: Global Tipping Points Nominated by Dr Andy Richards. Partnered with Potsdam Institute for Climate Impact Research (PIK); WWF UK. KTP with Qube Renewables Ltd No … Hawkes. Partnered with NEOM Nature Reserve. Health, Wellbeing and Life Sciences Award The Health, Wellbeing and Life Sciences Award recognises innovations that lead us to better mental and physical wellbeing. Potential innovations can include products, policies, services and community partnerships . Shortlisted Projects: DOLPHIN_VIVO (Diagnosis of LymPHoma IN VIVO) Nominated by Dr Alex Dudgeon. Partnered with University of Bristol; Gloucestershire Hospitals NHS Foundati … Meertens. Partnered with Ibex Innovations Ltd. Fair, Just and Inclusive Society Award The Fair, Just and Inclusive Society Award recognises innovations towards a more equitable, just and inclusive society. Potential innovations can include products, policies, services, community partnerships, and use of facilities. Shortlisted Projects: Exa
Senisca Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Senisca Teams Senisca Save Saved Exeter 21 Total Employees Year Founded: 2020 View Website Overview Jobs Offices Is This Your Company? Claim Profile Jobs at Senisca Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to overview Jobs at similar companies View All Camber Softw
2021 WINNERS & FINALISTS ⇽ OBN Awards 2021 | BioUK on Glue Up This is a past event. Registration is closed. View other BioUK events. Log In Close Please enter a valid email address e.g. [email protected] Email Address * If you input more than 0 characters your Email Address may not display properly Afghanistan | 🇦🇫 + 93 Aland Islands | 🇦🇽 + 358 Albania | 🇦🇱 + 355 Algeria | 🇩🇿 + 213 American Samoa | 🇦🇸 + 1684 Andorra | 🇦🇩 + 376 Angola | 🇦🇴 + 244 Anguilla | 🇦🇮 + 1264 Antarctica | 🇦🇶 + 672 Antigua and Barbuda | 🇦🇬 + 1268 Argentina | 🇦🇷 + 54 Armenia | 🇦🇲 + 374 Aruba | … NERS & FINALISTS Please click here ​ , for more information about our OBN Award Winners. Best Start-up Biotech Kindly Sponsored by: Thermo Fisher Scientific ​ Winner: SENISCA ​ Finalists: Novai ​ SWITCHRx ​ Best Start-Up Medtech Kindly Sponsored by: Penningtons Manches Cooper ​ Winner: Cerca Magnetics ​ Finalists: Koalaa ​ Charco Neurotech ​ Best Emerging Biotech Kindly Sponsored by: LifeSci Advisors ​ Winner: Artios … gics ​ Finalists: Healx ​ C4X Discovery ​ Special Recognition Award Kindly Sponsored by: Oxford Biomedica ​ Clive Dix CEO of C4X Discovery, Chairman of Centauri Therapeutics, and Non-Executive Director of the Medicines Discovery Catapult and until April 2021, Interim Chair of the UK Vaccine Taskforce. In recognition of his extensive achievements within the UK biotechnology industry and with many biotechs over more than 30 years. OBN Awards 2021 … input more than 0 characters your New Password may not display properly Cancel Submit Your password has expired. Change your password to continue. Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number , and one special character(!"#$%&'()*+,-./\:;?@[]^_`{|}~=) . Close Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number, and one special chara … input more than 0 characters your New Password may not display properly Cancel Submit Email Address Not Found Please go to My Profile and add an email address to continue with this action. Cancel
News – Precision Biosearch Precision Biosearch Menu About Us Our People Our Story Our Values Methodology Testimonials Contact News News Precision BioSearch supports AdvanCell to appoint Justyna Kelly as CTO Precision BioSearch supports AdvanCell to appoint Justyna Kelly as CTO • June 23, 2026 Precision BioSearch partners with MitoRx Therapeutics to appoint Alison Strutt as CFO Precision BioSearch partners with MitoRx Therapeutics to appoint Alison Strutt as CFO • June 16, 2026 Building a “super team” in biotech, honestly Building a “super team” in biotech, honestly • May 1, 2026 Precison